We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CAPA, Complaint Handling Bring Warning Letter to Stanmore

CAPA, Complaint Handling Bring Warning Letter to Stanmore

April 17, 2015

Stanmore Implants Worldwide, a manufacturer of extendable femur and knee-replacement devices, received an FDA warning letter for corrective and preventive action, complaint handling and auditing violations.

The Nov. 26 letter to the UK-based devicemaker says Stanmore’s CAPA procedures do not ensure that information is received by appropriate personnel.

The investigator also dinged the company’s corrective action procedures for not requiring documentation of CAPA activities. Investigators found a CAPA file closed as effective without confirming any corrective actions had been completed.

Another file, on corrective action to change plastic components related to the company’s ITAP prosthesis, did not contain adequate validation of the corrective action, the investigator found.

The FDA also criticizes the company’s complaint handling procedures, citing failure to evaluate complaints for MDR reportability, failure to document oral complaints upon receipt and failure to process complaints in a consistent and timely manner.

Further, the complaint handling procedure does not require that records of investigation include the nature of the complaint, device name and control number, or dates and results of the investigation, the letter says.

The FDA also rapped Stanmore’s quality audit system. According to the warning letter, the company violated a rule that auditors must not have responsibility for areas they audited in 2012 and 2013.

The FDA says that while Stanmore had revised these procedures since the July 2014 inspection, it remains unclear if personnel were trained in the new procedures and whether a retrospective review of complaints had been conducted.

The company did not respond to requests for comment. Read the letter at www.fdanews.com/04-14-15-Stanmore.pdf. — Charlotte Astor

Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing